# Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

> **NCT00023920** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Blastic Phase Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** idarubicin
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT00023920
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-07
- **Primary completion:** 2004-09
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023920, "Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00023920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*